Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Wednesday, December 2, 2009, 12:16AM ET - U.S. Markets open in 9 hours and 14 minutes. Dow Up 1.23% Nasdaq Up 1.46%
Sunesis Pharmaceuticals Inc. (SNSS)On Dec 1: 0.32  Up 0.00 (0.63%)  
MORE ON SNSS
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
Sunesis Pharmaceuticals Inc.
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States - Map
Phone: 650-266-3500
Fax: 650-266-3505
Web Site: http://www.sunesis-pharma.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:36

BUSINESS SUMMARY 
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. Its primary product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer in Phase 2 development stage. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in advanced platinum-resistant ovarian cancer patients. Sunesis Pharmaceuticals has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin. It was formerly known as Mosaic Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in South San Francisco, California.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Sunesis Pharmaceuticals Inc.


    CORPORATE GOVERNANCE 
    Sunesis Pharmaceuticals Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 55.7% of CGQ Universe companies and 30.6% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Mr. Daniel N. Swisher Jr., 45
    Chief Exec. Officer, Pres
    N/A N/A
    Mr. Eric H. Bjerkholt , 49
    Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. & Corp. Devel.
    N/A N/A
    Dr. Steven B. Ketchum Ph.D., 44
    Sr. VP of R&D
    N/A N/A
    Dr. Judith A. Fox Ph.D,
    VP of Product & Preclinical Devel.
    N/A N/A
    Dr. Glenn C. Michelson M.D.,
    VP of Clinical Strategy
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis